

Cadila Healthcare Ltd. - Consolidated Gross Sales Break-up

Rs. Mio.	Q4 14-15	Q4 13-14	% Gr y-y	YTD 14-15	YTD 13-14	% Gr y-y
Home Markets	17,133	13,627	25.7%	63,053	48,817	29.2%
India Formulations	6,797	6,247	8.8%	26,772	24,651	8.6%
US Formulations	9,789	6,783	44.3%	33,932	21,704	56.3%
Latin America Formulations	547	597	-8.3%	2,348	2,462	-4.6%
Other Markets	5,833	5,893	-1.0%	23,524	23,267	1.1%
Europe Formulations	740	845	-12.5%	3,376	3,902	-13.5%
Japan Formulations	0	144	-100.0%	0	541	-100.0%
Emerging Markets Formulations	1,117	953	17.2%	4,075	3,587	13.6%
Consumer Wellness	1,114	1,073	3.7%	4,430	4,296	3.1%
Animal Health & Others	823	745	10.5%	3,217	2,865	12.3%
APIs	870	939	-7.4%	3,723	3,497	6.5%
JVs and Alliances	1,169	1,192	-1.9%	4,704	4,580	2.7%
Grand Total	22,967	19,520	17.7%	86,577	72,084	20.1%

Cadila Healthcare Ltd.

Details of other incomes

Rs. Mio.	Q4 14-15	Q4 13-14	% Gr y-y	YTD 14-15	YTD 13-14	% Gr y-y
Other Operating Income	411	522	-21.2%	1,542	1,640	-6.0%
Dossier Fees		8	-100.0%		8	-100.0%
Royalty Income	8	75	-89.9%	390	301	29.4%
Net Gain on foreign currency transactions and translation (Refer Note below)		-24	100.0%		262	-100.0%
Others	403	462	-12.8%	1,152	1,069	7.8%

Note : There was a net loss of Rs. 190 Mio. on translation of inventories held by foreign subsidiaries, which has been included in Cost of Goods and a net loss of Rs.168 Mio. included in other expenses in Q4 14-15. Thus, on aggregate level, there was a loss of Rs. 358 Mio. on operating transactions (above EBIDTA line) in Q4 14-15 vs loss of Rs. 156 Mio. in Q4 13-14. See details below for more clarity.

Rs. Mio.	Q4 14-15	Q4 13-14	% Gr y-y	YTD 14-15	YTD 13-14	% Gr y-y
Other Income	203	131	55.1%	554	507	9.3%
Interest & Dividend income	132	115	14.5%	413	388	6.5%
Profit on sale of investments	5	4	13.7%	33	62	-46.7%
Profit on sale of assets	1	0		2	0	
Others	66	12	454.8%	106	57	84.9%

Details of Foreign Exchange Fluctuations

Rs. Mio. (+ = loss, - = gain)	Q4 14-15	Q4 13-14	% Gr y-y	YTD 14-15	YTD 13-14	% Gr y-y
A. On operating transactions (above EBIDTA line)	358	156	129.5%	284	359	-20.9%
a. Included in other income		24	-100.0%		-262	100.0%
b. Included in sales					550	-100.0%
c. Included in cost of goods	190	132	43.9%	100	71	40.8%
d. Included in other expenses	168			184		
B. On Foreign Currency Borrowings (part of interest cost)	42	-31	235.5%	66	-278	123.7%
Total Foreign Currency Fluctuations (+ = loss, - = gain)	400	125	220.0%	350	81	332.1%

Details of R&D Expenses

Rs. Mio.	Q4 14-15	Q4 13-14	% Gr y-y	YTD 14-15	YTD 13-14	% Gr y-y
Total R&D Expenses	1,488	1,033	44.0%	5,606	4,608	21.7%

Consolidated Capex for 2014-15

**Rs. 3829
Mio.**

R&D capex included in above for 2014-15

**Rs. 315
Mio.**